BMJ: The effect of atorvastatin on the prognosis of critically ill patients with new coronary pneumonia in ICU

Covid-19 can cause multiple target organ abnormalities, and an overactive immune response can lead to pulmonary and extrapulmonary damage, of which lung parenchyma damage is the most common and dangerous feature of severe Covid-19 patients, which can develop into acute respiratory distress syndrome
.

Under conditions of vascular endothelial activation, critically ill patients are at increased risk of microthrombi and macrothrombi, and venous thromboembolism in the ICU is associated with extremely high morbidity and mortality

Immune Vascular Thrombosis Researchers have assessed the effect of statins on clinical outcomes in Covid-19 patients admitted to the intensive care unit (ICU)

The primary endpoint occurred in 95 (33%) patients in the atorvastatin group and 108 (36%) in the placebo group, odds ratio 0.
84

Effects of atorvastatin therapy on patient outcomes

Effects of atorvastatin therapy on patient outcomes

The study found that in adults with severe Covid-19 admitted to the ICU, atorvastatin treatment did not reduce the risk of thrombosis, extracorporeal membrane oxygenation, or all-cause mortality, and had no significant effect on improving patient outcomes
.

In adults with severe Covid-19 admitted to the ICU, atorvastatin treatment did not reduce the risk of thrombosis, extracorporeal membrane oxygenation, or all-cause mortality, and had no significant effect on improving patient outcomes
.
In adults with severe Covid-19 admitted to the ICU, atorvastatin treatment did not reduce the risk of thrombosis, extracorporeal membrane oxygenation, or all-cause mortality, and had no significant effect on improving patient outcomes
.

Original source:
Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
Leave a comment here